Life-threatening hyperglycemia and acidosis related to olanzapine: A case report and review of the literature

Journal of Intensive Care Medicine

Volumn 22, Issue 1, 2007, Pages 52-55

  Varma, Mritunjay Kumar ^a   Connolly, Karen ^a   Fulton, Barbara ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antipsychotics; Diabetic ketoacidosis; Hyperglycemia; Olanzapine

Indexed keywords

AMYLASE; ANTIBIOTIC AGENT; CREATINE KINASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; ESCHERICHIA COLI; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; INSULIN TREATMENT; INTENSIVE CARE UNIT; LEUKOCYTOSIS; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION; URINE CULTURE; WARD;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPERGLYCEMIA;

EID: 33846025402     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606295823     Document Type: Article

References (28)

1. Kane JM. Pharmacological treatment of schizophrenia. Biol Psychiatry. 1999 ; 46: 1396-1408.
2. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001 ; 15: 537-551.
3. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002 ; 325: 243-247.
4. Haupt DW, Newcomer JW. Hyperglycaemia and antipsychotic medications. J Clin Psychiatry. 2001 ; 62 (suppl 27). 15-26.
5. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand. 2002 ; 105: 253-256.
6. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002 ; 22: 841-845.
7. Melkersson K, Hulting AL. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine. Psychosomatics. 2002 ; 43: 67-70.
8. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002 ; 59: 337-345.
9. Ragucci KR, Wells BJ. Olanzapine induced diabetic ketoacidosis. Ann Pharmacother. 2001 ; 35: 1556-1558.
10. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002 ; 63: 1135-1139.
11. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002 ; 149: 59-64.
12. Buch H, Clifford G, Barton D, Scarpello J. Diabetic ketoacidosis secondary to olanzapine. Br J Diabetes Vasc Dis. 2003 ; 3: 373-374.
13. Cassidy F, Ahearan E, Croll BJ. Elevated frequency of diabetes mellitus in hospitalised maniac depressive patients. Am J Psychiatry. 1999 ; 156: 1417-1420.
14. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric in patients with bipolar 1 affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002 ; 73: 301-302.
15. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002 ; 16: 77-89.
16. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994 ; 17: 961-969.
17. Colditz GA, Willet WC, Rotnitzky A, Manson JE. Weight gain as risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995 ; 122: 481-486.
18. Baumgart U, Schmid R, Spiessl H. Olanzapine-induced acute rhabdomyolysis: a case report. Pharmacopsychiatry. 2005 ; 38: 36-37.
19. Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001 ; 35: 1020-1022.
20. Shuster J. Adverse drug reaction. Nursing. 2000 ; 30: 87-87.
21. Marcus EL, Vass A, Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother. 1999 ; 33: 697-700.
22. Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother. 1999 ; 33: 787-789.
23. Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clin Neuropharmacol. 1998 ; 30: 239-245.
24. Devinsky O, Pacia SV. Seizure during clozapine therapy. J Clin Psychiatry. 1994 ; 55 (9 suppl B). 153-156.
25. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997 ; 53: 281-298.
26. Lindenmayer JP, Patel R. Olanzapine induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999 ; 156: 1471-1471.
27. Taylor S. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001 ; 16: 63-73.
28. Expert Group. "Schizophrenia & Diabetes" expert consensus meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl. 2004 ; 47: 112-114.